Departamento de Molestias Infecciosas e Parasitarias, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil; LIM-49, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
Departamento de Molestias Infecciosas e Parasitarias, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil; LIM-49, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil; Divisao de Molestias Infecciosas e Parasitarias do Hospital das Clínicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.
Vaccine. 2024 Nov 14;42(25):126114. doi: 10.1016/j.vaccine.2024.07.015. Epub 2024 Jul 16.
We aimed to characterise vaccine-induced protection against COVID-19 during five waves caused by Variants of Concern (VOCs). This is a nested case-control study of 3,972 HCW primarily vaccinated with CoronaVac (98%) that evaluated symptomatic SARS-CoV-2 breakthrough infections (BI) in almost two-years follow-up until the 3rd Omicron wave. Predictors of protection against SARS-CoV-2 BI were analysed using conditional logistic regression models. We included 1,491 SARS-CoV-2 breakthrough cases, mostly mild, and 2,962 controls. Most participants (90%) had received at least one booster before the onset of the Omicron waves, mainly BNT162b2. A multivariate logistic regression showed that vaccine-induced protection against BI wanes after six months regardless of the number of monovalent booster doses. Additionally, booster dose with BNT162b2 showed a trend for higher protection compared to CoronaVac during the Omicron waves. In conclusion, immunity of monovalent booster doses against SARS-CoV-2 is short-lasting. Individuals previously vaccinated with an inactivated vaccine should receive a BNT162B2 booster dose.
我们旨在描述在五次由关注变种(VOC)引起的 COVID-19 浪潮中,疫苗对 COVID-19 的诱导保护作用。这是一项针对 3972 名主要接种科兴疫苗(98%)的 HCW 的嵌套病例对照研究,评估了近两年来,直到第三波奥密克戎浪潮,针对 SARS-CoV-2 突破感染(BI)的症状。使用条件逻辑回归模型分析了对 SARS-CoV-2 BI 的保护预测因素。我们纳入了 1491 例 SARS-CoV-2 突破病例,大多数为轻症,以及 2962 例对照。大多数参与者(90%)在奥密克戎波之前至少接受过一次加强针接种,主要是 BNT162b2。多变量逻辑回归显示,无论单剂加强针的剂量多少,疫苗对 BI 的诱导保护在六个月后都会减弱。此外,在奥密克戎波期间,BNT162b2 加强针与科兴疫苗相比,具有更高的保护作用趋势。总之,单剂加强针针对 SARS-CoV-2 的免疫作用持续时间短。先前接种过灭活疫苗的个体应接种 BNT162B2 加强针。